 Connection
Alexander Burnett to Ovarian Neoplasms
This is a "connection" page, showing publications Alexander Burnett has written about Ovarian Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.225 |
|
|
|
-
Goyne HE, Stone PJ, Burnett AF, Cannon MJ. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 2014 Apr; 37(3):163-9.
Score: 0.087
-
Santin AD, Can? S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005 May 15; 65(10):4334-42.
Score: 0.047
-
Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest. 2005; 23(8):665-70.
Score: 0.046
-
Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004 Dec; 95(3):496-9.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|